@article{f81834288ee4438a88beb2bd58ed2716,
title = "The expression of cd74-regulated inflammatory markers in stage iv melanoma: Risk of cns metastasis and patient survival",
abstract = "Innate inflammatory features have been found in melanoma tumors from patients at all stages, and molecular analysis has identified definitive inflammatory proteins expressed by tumors cells in patients who presents the worst prognosis. We have previously observed weakened outcomes in patients with constitutive expression of inducible nitric oxide synthase (iNOS), macrophage migration inhibitory factor (MIF) and improved outcomes with CD74 expression in stage III melanoma. In our current study, we tested our hypothesis on CD74-regulated inflammatory markers{\textquoteright} expression in stage IV melanoma tumors whether the signature is associated with survival outcome and/or risk of developing CNS metastasis. We retrospectively identified 315 patients with stage IV melanoma. In a tissue microarray (TMA), we examined the expression of cells with CD74, its receptor MIF, and downstream inflammatory markers iNOS, nitrotyrosine (NT), cyclooxygenase (COX)-2 and microsomal prostaglandin E synthase-1 (mPGES1). We analyzed the association of those inflammatory markers with overall survival time (OS) and time to CNS metastasis using Kaplan–Meier survival analyses. Our data validates CD74 as a useful prognostic tumor cell protein marker associated with favorable OS as in stage III melanomas, while the tumor NT expression strongly predicts an increased risk of developing CNS metastasis (p = 0.0008) in those patients.",
keywords = "CD74, CNS metastasis, Melanoma, Nitrotyrosine, Prognosis, Stage IV",
author = "Dai Ogata and Jason Roszik and Junna Oba and Kim, {Sun Hee} and Bassett, {Roland L.} and Haydu, {Lauren E.} and Keiji Tanese and Grimm, {Elizabeth A.} and Suhendan Ekmekcioglu",
note = "Funding Information: Funding: This work was supported by The University of Texas, MD Anderson Cancer SPORE in Melanoma (P50-CA093459), MD Anderson Cancer Center Support Grant (P30-CA016672), Foundation for the National Institutes of Health (FNIH)-PACT, Miriam and Sheldon G. Adelson Medical Research Foundation, Jim Mulva Foundation, and the AIM at Melanoma Foundations. Scientific and financial support for the PACT project are made possible through funding support provided to the FNIH by: AbbVie Inc., Amgen Inc., Boehringer-Ingelheim Pharma GmbH & Co. KG, Bristol-Myers Squibb, Celgene Corporation, Genentech Inc., Gilead, GlaxoSmithKline plc, Janssen Pharmaceutical Companies of Johnson & Johnson, Novartis Institutes for Biomedical Research, Pfizer Inc., and Sanofi. Funding Information: This work was supported by The University of Texas, MD Anderson Cancer SPORE in Melanoma (P50-CA093459), MD Anderson Cancer Center Support Grant (P30-CA016672), Foundation for the National Institutes of Health (FNIH)-PACT, Miriam and Sheldon G. Adelson Medical Research Foundation, Jim Mulva Foundation, and the AIM at Melanoma Foundations. Scientific and financial support for the PACT project are made possible through funding support provided to the FNIH by: AbbVie Inc., Amgen Inc., Boehringer-Ingelheim Pharma GmbH & Co. KG, Bristol-Myers Squibb, Celgene Corporation, Genentech Inc., Gilead, GlaxoSmithKline plc, Janssen Pharmaceutical Companies of Johnson & Johnson, Novartis Institutes for Biomedical Research, Pfizer Inc., and Sanofi. Publisher Copyright: {\textcopyright} 2020 by the authors. Licensee MDPI, Basel, Switzerland.",
year = "2020",
month = dec,
doi = "10.3390/cancers12123754",
language = "English",
volume = "12",
pages = "1--13",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "12",
}
